• Google Scholar Search for Shotaro Hoshino in:Nature Research journals • PubMed • Google Scholar Search for Zhijuan Hu in:Nature Research journals • PubMed • Google Scholar Search for Junko Hashimoto
Nakamura Hiroyuki Osada Shunji Takahashi Kazuo Shin-ya Haruo Ikeda Junko Hashimoto Ikuko Kozone Miho Izumikawa OPEN Published: xx xx xxxx Telomestatin, a strong telomerase inhibitor with G-quadruplex
IBN after withdrawal of PTH. Compliance with Ethical Standards Conflict of interest Satoshi Takeda, Sadaoki Sakai, Keisuke Tanaka, Haruna Tomizawa, Kenichi Serizawa, Kenji Yogo, Junko Hashimoto, Koichi
Ibandronate is a drug widely used outside Japan for the treatment of osteoporosis. It is available in formulations for intermittent intravenous (i.v.) administration and for intermittent (once monthly) oral administration. Ibandronate was recently approved in Japan as an i.v. injection with a dosing regimen of 1.0 mg once a month. To establish the optimal dose for oral...
Corp., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. Seitaro Yoshida, Junko Hashimoto, Masayuki Matsunaga, and Masato Tobinai are employees of Chugai
Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. Junko Hashimoto and Masato Tobinai are employees of Chugai Pharmaceutical Co. Ltd. Hideki Mizunuma has received consulting fees from Chugai Pharmaceutical Co. Ltd